## **Amendment to the Claims:**

Claims 1, 6-12 and 16-22 have been cancelled previously. And claims 4, 5, 13 and 14 have been amended herein.

Claim 1 (cancelled)

Claim 2 (previously amended):

The method of claim 13, wherein said recombinant viral vector is a retroviral vector.

Claim 3 (previously amended):

The method of claim 13, wherein said recombinant vector is a plasmid vector.

Claim 4 (currently amended):

The method of claim 13, wherein said population of transfected/transduced chondrocyte cells transfected chondrocytes are stored prior to transplantation.

Claim 5 (currently amended):

The method of claim 4, wherein said population of transfected/transduced chondrocyte cells transfected chondrocytes are stored in 10% DMSO under liquid nitrogen prior to transplantation.

Claims 6-12 (cancelled)

Claim 13 (currently amended):

A method of regenerating generating hyaline cartilage, comprising:

a) generating a recombinant viral or plasmid vector comprising a DNA sequence encoding transforming growth factor  $\beta$ 1 (TGF- $\beta$ 1) or BMP operatively linked to a promoter;

b) transfecting/transducing transfecting in vitro a population of chondrocyte cells chondrocytes with said recombinant vector, resulting in a population of transfected/transduced transfected connective tissue cells; and

c) injecting a composition consisting of the transfected/transduced transfected population of ehondrocyte cells chondrocytes and a pharmaceutically acceptable carrier into a joint space of a mammal such that expression of the DNA sequence encoding TGFβ1 or BMP within the joint space occurs resulting in the generation of hyaline cartilage in the joint space.

Claim 14 (currently amended):

The method of claim 13, wherein said transfection is accomplished by liposome encapsulation, calcium phosphate coprecipitation, electroporation and or DEAE-dextran mediation.

Claim 15 (original):

The method of claim 3, wherein said plasmid is  $pmT\beta1$ .

Claims 16-22 (cancelled)